



March 23, 2017

Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress

Poster selected as one of the best in a poster session during the 32nd Annual EAU Congress

SAN DIEGO and VANCOUVER, British Columbia, March 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that data from its successful Phase 2a study of topsalysin, which evaluated the drug as a focal treatment for localized prostate cancer, will be presented as a poster on March 26, 2017 at the 32nd Annual European Association of Urology in London, UK. The poster has been selected by conference organizers as one of the best posters at the congress.



sophiris

Abstract No. 758: "Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study"

Presenting Author: Dr. Yaalini Shanmugabavan, Division of Surgery and Interventional Sciences, University College London, London, UK

Poster Session: Poster Session 57 - Prostate cancer: Is the future focal?

Time: March 26, 2017 from 3:45 pm - 5:15 pm GMT

The abstract related to the poster can be accessed through the European Association of Urology Congress website at <http://eau17.uroweb.org/>.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells. More than 400 patients have received treatment with topsalysin, which continues to appear to be safe and well tolerated. For more information, please visit www.sophirisbio.com.

Company Contact:

Peter Slover
Chief Financial Officer
(858) 777-1760

Corporate Communications and Media Contact:

Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/topsalysin-data-from-successful-phase-2a-localized-prostate-cancer-study-to-be-presented-at-the-32nd-european-association-of-urology-congress-300428644.html>

SOURCE Sophiris Bio Inc.

News Provided by Acquire Media